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ABSTRACT
Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the acquisition of HIV-1 infection. Vaccine
effectiveness will depend on the extent to which induced antibodies neutralize the global diversity of circulating HIV-1 variants.
Using large panels of genetically and geographically diverse HIV-1 Env-pseudotyped viruses and chronic infection plasma sam-
ples, we unambiguously show that cross-clade nAb responses are commonly induced in response to infection by any virus clade.
Nonetheless, neutralization was significantly greater when the plasma clade matched the clade of the virus being tested. This
within-clade advantage was diminished in older, more-diverse epidemics in southern Africa, the United States, and Europe com-
pared to more recent epidemics in Asia. It was most pronounced for circulating recombinant form (CRF) 07_BC, which is com-
mon in China and is the least-divergent lineage studied; this was followed by the slightly more diverse Asian CRF01_AE. We
found no evidence that transmitted/founder viruses are generally more susceptible to neutralization and are therefore easier
targets for vaccination than chronic viruses. Features of the gp120 V1V2 loop, in particular, length, net charge, and number of
N-linked glycans, were associated with Env susceptibility and plasma neutralization potency in a manner consistent with neu-
tralization escape being a force that drives viral diversification and plasma neutralization breadth. The overall susceptibility of
Envs and potencies of plasma samples were highly predictive of the neutralization outcome of any single virus-plasma combina-
tion. These findings highlight important considerations for the design and testing of candidate HIV-1 vaccines that aim to elicit
effective nAbs.
IMPORTANCE
An effective HIV-1 vaccine will need to overcome the extraordinary variability of the virus, which is most pronounced in the en-
velope glycoproteins (Env), which are the sole targets for neutralizing antibodies (nAbs). Distinct genetic lineages, or clades, of
HIV-1 occur in different locales that may require special consideration when designing and testing vaccines candidates. We show
that nAb responses to HIV-1 infection are generally active across clades but are most potent within clades. Because effective vac-
cine-induced nAbs are likely to share these properties, optimal coverage of a particular clade or combination of clades may re-
quire clade-matched immunogens. Optimal within-clade coverage might be easier to achieve in regions such as China and Thai-
land, where the epidemic is more recent and the virus less diverse than in southern Africa, the United States, and Europe. Finally,
features of the first and second hypervariable regions of gp120 (V1V2) may be critical for optimal vaccine design.
HIV-1 exhibits extraordinary sequence variation in its surfacegp120 and transmembrane gp41 envelope glycoproteins
(Env), which are the sole targets for neutralizing antibodies
(nAbs) (1). This variation contributes to the diversity manifested
in multiple genetic subtypes, or clades, and a growing number of
circulating recombinant forms (CRFs) that differ in prevalence by
geographic region (2, 3). Escape from the immune response to the
virus during infection fuels the generation of much of this diver-
sity. A vaccine that aims to elicit an effective nAb response will
need to overcome this genetic variation at the antigenic level, at
least within a given subtype or geographic region, but preferen-
tially across all major subtypes in regions where HIV-1 is most
prevalent. Unfortunately, despite an ability of current vaccines to
induce moderate to high titers of nAbs against highly neutraliza-
tion-sensitive strains of the virus (i.e., tier 1 phenotype) (4), these
antibodies exhibit little if any neutralizing activity against the less
sensitive but more common tier 2 circulating strains (5–10) and
have failed to demonstrate a significant level of protection in phase
3 clinical trials of Env-containing vaccines (11–13). In addition,
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there is no clear evidence that the relatively weak nAb response
seen in the RV144 Thai trial (5, 14) was associated with the modest
protection observed in this trial (15).
The relatively weak and ineffective vaccine-elicited nAb re-
sponses in clinical trials have stimulated a heightened interest in
studies of broadly neutralizing antibody (bnAb) responses during
chronic HIV-1 infection. This focus provides a way to gain infor-
mation on what should ultimately be possible to elicit by vaccina-
tion, helps refine our knowledge regarding viral epitopes that are
particularly susceptible to bnAbs, and enables common character-
istics of bnAbs to be defined, thus informing strategies for design-
ing improved vaccine immunogens (16). During chronic infec-
tion, most people make antibodies that cross-neutralize multiple
tier 2 variants of different clades (17). A small number of individ-
uals make high titers of antibodies that neutralize most tier 2
strains evaluated (17–24). Studies of monoclonal antibodies from
the latter set of individuals have shown that at least five regions on
the Env trimer spike are vulnerable to bnAbs. These regions in-
clude conformational epitopes in the CD4 binding site (CD4bs) of
gp120, glycan-dependent conformational epitopes in the V1V2
loop and at the base of V3/C3 of gp120, linear epitopes in the
membrane-proximal external region (MPER) of gp41 (reviewed
in references 25, 26, 27, and 28), and a more recently described
conformational epitope at the gp120-gp41 interface (29). These
epitope regions and contacts span both variable and highly con-
served amino acids in Env; the breadth exhibited by these bnAbs is
enabled by their capacity to recognize conserved aspects of the
epitopes across diverse viruses despite some intrinsic local diver-
sity of the virus in epitope regions. Other regions of vulnerability
that have yet to be identified with current monoclonal antibodies
and epitope mapping strategies might exist.
Increasing knowledge of the biological processes that initiate
and govern the production of bnAbs is leading to new ideas for
immunogen design. The evolutionary trajectory of clonal lineages
of antibodies that eventually develop breadth has successfully
been reconstructed for some of the most potent bnAbs isolated to
date (30–32), allowing inference of their germ line precursors and
design of antigens that trigger B cell precursors known to initiate
likely lineages (33, 34). Furthermore, immune selection drives vi-
ral escape, resulting in coevolving populations of virus and anti-
bodies in serum and a sustained dynamic of escape and pursuit.
The study of subjects followed longitudinally from acute viremia
through bnAb development in chronic infection has enabled
identification of stages involved in antibody-virus coevolution. In
a study by Liao et al. (35), epitope diversification due to escape
from autologous neutralization preceded breadth and heterolo-
gous neutralization in a bnAb clonal lineage. This observation
supports the idea that exposure to epitope variants through vac-
cination may foster the evolution of antibody breadth (36). It also
provides key data to allow a vaccine approach that attempts to
reproduce the evolutionary trajectory of bnAb responses by in-
ducing ancestral intermediates of bnAbs (37, 38). This informa-
tion, combined with other strategies that aim to mimic the native
structure of functional Env spikes (39–41) and to overcome self-
tolerance mechanisms (42) and the immunosuppressive proper-
ties of Env (43–45) that impede B cell maturation and survival, are
just a few examples of the potential to discover improved vaccine
immunogens in the near future. Vaccines that elicit bnAbs against
one or more highly conserved epitopes across multiple clades of
the virus are desirable; however, a more feasible and still useful
goal may be to elicit multiple responses to less-conserved epitopes
that exhibit moderate variability within and between clades (17).
As newer immunogens are developed and tested, it will be im-
portant to consider how Env diversity will impact the ability of the
vaccine-elicited Abs to neutralize virus variants in different parts
of the world. Early studies found little evidence that the different
genetic subtypes of HIV-1 corresponded to distinct neutralization
serotypes (46–50); the only exception was an ability to distinguish
clade B viruses from CRF01 viruses using HIV-1 plasma samples
of both clades (47, 48). These early studies were performed with
relatively small numbers of samples and were confounded by the
use of nonclonal viruses. A subsequent study with a larger number
of molecularly cloned Env-pseudotyped viruses and a single pool
of HIV-1 plasma samples for each of six subtypes showed that the
clade C plasma pool was superior to the others for neutralization
of multiple subtypes of the virus (51). This study also found mul-
tiple cases of preferential intrasubtype neutralization when the
corresponding uncloned virus quasispecies were assayed in hu-
man peripheral blood mononuclear cells (PBMC), and it yielded
supporting evidence that clade B and CRF01 viruses form two
antigenically distinct neutralization serotypes relative to each
other. Another study found evidence for regional clustering of
shared neutralization determinants on clade C viruses from South
Africa (52). Finally, some of the less potent bnAbs exhibit prefer-
ential neutralization of clade-matched viruses (31, 53). Two of the
most dramatic examples are 2G12 and 2F5, which came from
clade B-infected individuals and exhibit substantial breadth
against clade B viruses but rarely neutralize clade C viruses (52–
56). Differences in neutralization breadth also have been observed
with clonally related bnAbs targeting a single epitope (31, 57).
In contrast to the extensive recent work characterizing bnAb
breadth, here we inform a broader view of shared characteristics
and patterns of serological potency and breadth in natural infec-
tion and begin to define determinants of tier 2 virus neutralization
sensitivity. This was done by utilizing an exceptionally large neu-
tralization data set comprised of 219 molecularly cloned Env-
pseudotyped viruses assayed with 205 plasma samples from
HIV-1 infections, where both the Envs and plasma samples were
chosen to represent the diversity of predominant M-group clades
and circulating recombinant forms. A recent evaluation of this
data set helped to clarify the spectrum of neutralization breadth
seen during chronic HIV-1 infection (17) and was used to identify
a global panel of HIV-1 Env reference strains for standardized
assessments of vaccine-elicited nAb responses across multiple vac-
cine platforms in different parts of the world (58). Here we present
an analysis to address the relative contributions of cross-reactive
interactions within and between clades for both the plasma sam-
ples and viruses, the effects of clade diversity and divergence on
neutralization susceptibility, and the contributions of gp120 hy-
pervariable regions to neutralization.
MATERIALS AND METHODS
Plasma samples and viruses. All plasma samples and Env-pseudotyped
viruses used in this study were described previously (17, 58). Briefly,
plasma samples were obtained from 205 chronically infected individuals
who were antiretroviral drug naive and infected with HIV-1 subtypes A
(n  8), B (n  59), C (n  58), and D (n  2); with circulating recom-
binant forms CRF01_AE (n  14), CRF07_BC (n  16), CFR02_AG (n 
2), and CRF10_CD (n  1); and with noncirculating recombinants AC
(n  4), AD (n  3), BD (n  1), CD (n  1), and ABCD (n  2).
Sequences could not be obtained for 34 individuals due to low levels of
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plasma viremia, so the infecting clade of the virus was undetermined in
these cases. HIV-1 genetic subtypes of plasma samples were determined
by single-genome amplification (SGA) and sequencing of a single gp160
gene. All plasma samples were tested for nonspecific activity in neutral-
ization assays with murine leukemia virus (MLV) Env-pseudotyped virus.
Samples that tested positive (50% inhibitory dose [ID50]  1:40) were not
included. For assay results that did not give ID50 values, a small constant
placeholder value of 10 was recorded; we refer to these as “censored”
values, because the ID50 values were not directly observed, being below the
limit of detection.
Functional full-length rev-env cassettes used for Env-pseudotyped vi-
ruses were cloned by SGA from plasma viral RNA of 219 subjects infected
with HIV-1 clades A (n  10), B (n  54), C (n  67), D (n  5), G (n 
8), CRF01_AE (n  21), CRF02_AG (n  16), CRF06 (n  1), CRF07_BC
(n  14), AC (n  6), AD (n  5), ACD (n  1), BC (n  4), BG (n  1),
and CD (n  6). Because Fiebig stages (59) were frequently unknown or
ranged in value, we defined three infection stage categories: early (Fiebig I
through IV), intermediate (Fiebig V through early VI), and late (late
Fiebig VI, 6 or more months postinfection through chronic infection),
where known. As described throughout the text, some analysis considered
only viruses with early or late designations, although we also tried some
comparisons that grouped intermediate with early and some that grouped
intermediate with late. This was done because we did not know a priori
whether the intermediate-stage group should be treated as early, late, or
independent, and we were mindful of biases due to uneven sampling
across clades (Table 1).
Neutralization assay. Neutralization of Env-pseudotyped viruses was
measured in 96-well culture plates by using Tat-regulated firefly luciferase
(Luc) reporter gene expression to quantify reductions in virus infection in
TZM-bl cells (60). This assay has been formally optimized and validated
(61). Briefly, heat-inactivated (56°C, 1 h) plasma samples were assayed at
3-fold dilutions starting at 1:20. Neutralization titers (ID50) are the plasma
dilutions at which relative luminescence units (RLU) were reduced by
50% compared to RLU in virus control wells after subtraction of back-
ground RLU in cell control wells. Assay stocks of Env-pseudotyped viruses
were produced by transfection in 293T cells and titrated in TZM-bl cells as
described previously (60). Because the assays were conducted in three
different laboratories (Duke University, Harvard University, and NIH),
all plasma samples that were assayed in more than one laboratory were
evaluated with a standard set of three viruses (Bal.26, SF162.LS, and
Bx08.16) to document the equivalency of sample performance across
these laboratories. Any samples that did not meet the predefined criteria
for equivalency (ID50 agreement within a 3-fold difference range among
the laboratories for all 3 viruses) were not included. All three laboratories
also participated in a formal proficiency testing program for the TZM-bl
assay (62) during the course of this study. As an additional control for
uniform assay performance, HIVIG (polyclonal IgG from a pool of HIV-
1-positive plasma samples) was assayed with a single virus (SS1196.1) for
each batch of assays performed. The titer obtained was required to be
within a 3-fold difference range of a preestablished reference value. Assay
batches that did not meet this prespecified standard were repeated.
Sequence analysis. We aligned the 434 env sequences and HXB2
with GeneCutter (hiv.lanl.gov/content/sequence/GENE_CUTTER
/cutter.html), which aims to maintain intact codons for translation and
uses HMMer (63) with probability profiles trained specifically for HIV-1.
We then manually refined the alignment with Se-Al (64), computed phy-
logenies using PhyML, version 3.0 (65), with the HIVb4I substitu-
tion model (66), and rendered them in R, v3.0.2 (67), using the package
APE, v3.0-11 (68). We excluded hypervariable loops from phylogenetic
analysis and similarity comparisons to emphasize the phylogenetic signal.
We computed similarity between each pair of plasma sample and virus
Envs as percent identity over the length of the gp160 sequence, with
gapped sites excluded. The alignments and neutralization data are available
online (http://hiv.lanl.gov/content/sequence/HIV/USER_ALIGNMENTS/
Montefiori2014).
For population level alignments, an insertion/deletion mode of muta-
tion predominates in hypervariable loops. Length polymorphisms in
alignments of the hypervariable regions within the V loops from unlinked
infections lack phylogenetic signal identified by established base substitu-
tion models. For this reason, we treated them separately and instead sum-
marized hypervariable region lengths, the number of putative N-linked
glycosylation sites (PNGs), and the net charge excised from the hypervari-
able regions in V1, V2, V4, and V5. To define the boundaries of the hy-
pervariable regions, we identified the borders demarking transitions be-
tween locations where the alignment is reasonable and variation is most
commonly generated by point mutations and the short hypervariable re-
gions where insertions and deletions dominate sequence variation (69).
To characterize hypervariable regions, we excised the regions between the






At virus infection stage:
Total Not screened ScreeneddEa Ib Lc Unknownf
A 10 6 2 1 1 8 4 4
B 53 32 7 11 3 59 53 6
C 67 30 26 7 4 58 7 51
D 5 4 0 0 1 2 1 1
G 8 0 1 6 2 0 0 0
CRF01 21 8 0 10 3 14 14 0
CRF02 16 0 0 15 1 2 2 0
CRF07 14 2 0 12 0 16 0 16
Othere 25 3 9 6 7 12 6 6
Unknownf 0 0 0 0 0 34 30 4
Total 219 85 45 67 22 205 117 88
a Fiebig I through IV (early).
b Fiebig V through early Fiebig VI (intermediate).
c Late Fiebig VI through chronic.
d Number of plasma samples screened for neutralization potency and breadth.
e URFs and uniquely represented CRFs.
f Clade unknown because sequence amplification was unsuccessful.
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more conserved, easily aligned stretches. A web tool at the Los Alamos
HIV-1 database excises and characterizes either complete V loops or the
hypervariable regions within them, given an HIV Env alignment (http:
//hiv.lanl.gov/content/sequence/VAR_REG_CHAR/). The complete de-
tails of our strategy are provided there and in Text S1 in the supplemental
material. The regions bounding the hypervariable stretches also are noted in
the annotation at the HIV database (http://hiv.lanl.gov/content/sequence
/HIV/MAP/annotation.html).
To test for dual CRF01 infections in the B-clade plasma samples, 30
sequences were obtained from each plasma sample (T500108_503963 and
T500105_286588) to test for the presence of minority CRF01 populations.
A sample size of 30 was chosen to obtain power to detect minority variants
as follows: for a minority population of 15%, 30 sequences give over 99%
chance of sampling it. For a 10% minority population, 30 sequences give
95.8% chance of sampling; a 5% minority population has 78.5% proba-
bility of detection with 30 sequences, and a 1% population gives 26%
detection probability (70).
Statistical inference. For each of the clade A, B, C, CRF01, CRF02, and
CRF07 plasma samples, we computed the geometric mean within- and
between-clade ID50s using assay results from non-URF (unique recombi-
nant forms) Env pseudoviruses. We excluded the URFs to reduce noise
from mixed specificities due to recombination breakpoints at varied loca-
tions over gp160. Between-clade comparisons excluded those between
CRF07 and clade C viruses, due to the predominance of clade C Env in
CRF07. We compared within- and between-clade geometric mean titers
per plasma with paired, two-sided Wilcoxon tests. We used R, version
3.0.2 (67), to perform all tests. For comparisons between V-loop attri-
butes (length, number of putative N-linked glycosylation sites, and net
charge), we used Kendall’s  as implemented in the package Kendall, v 2.2
(71). We conducted 360 tests: 3 response variables (50% inhibitory con-
centration [IC50], IC80, and pAUC), 5 hypervariable regions (V1 and V2
combined, V1, V2, V4, and V5)  3 loop attributes (length, net charge,
number of glycosylation sites)  2 Env sources (the pseudoviruses and
plasma-derived Envs)  2 with and without low-titer plasma samples (to
adjust for screening)  2 with and without censored values as placehold-
ers (i.e., all assay results versus only reactive-assay results). We computed
false-discovery rates with the q-value package v 1.36.0 (72) after the
method of Storey and Tibshirani (73) and required a q of 0.1 for signif-
icant support. Curiously, although the direction and trends were consis-
tent between the methods, the pAUC scoring was less sensitive than ID50
in terms of the significance of correlations between loop attributes and
neutralization sensitivity. This was true even when we excluded censored
data from the ID50 analysis, so it was not due to a statistical artifact intro-
duced by inclusion of censored data that resulted in calculating inappro-
priate P values. The difference may be due at least in part to noise intro-
duced by assigning ranks to pAUC scores with low values and larger
proportional error.
We used mixed-effects linear regression to model neutralization out-
comes due to fixed effects of biological interest (matched plasma and virus
clades, whether the virus was obtained from an early or late infection, and
V1V2 lengths from plasma and virus Envs) while considering random
effects of the experimental design (plasma and virus), as described in Text
S2 in the supplemental material. Logistic regression uses the logit function
ln [P/(1 	 P)], where P is the binomial-outcome probability, to model
factors as additive effects to the (natural) log of the odds of the binary
outcome. Even odds correspond to a parameter estimate of zero (ln 1:1).
Model selection was performed via comparison with simpler, reduced
models by comparing Akaike Information Criterion scores computed in
analysis of variance (ANOVA) (74). Random-effects grouping factors
were virus and plasma. The checkerboard layout of experimental interac-
tions between each virus and plasma gives a completely crossed design.
Treating plasma and virus as random effects prevents the risk of pseu-
doreplication by adjusting the model matrix during parameter estimation
(74). That is, the random effects represent the variance-covariance struc-
ture of the crossed-factor experimental design rather than treat as inde-
pendent all 44,758 assays. To estimate model parameters, we used the
glmer method of the package lme4 (v 1.1-0) (75).
Row/column effects. Computing expected values (geometric means)
provided individual pseudovirus Env susceptibility scores and individual
plasma potency scores such that each combined virus-plasma (row/col-
umn) score approximates the log-transformed neutralization titers for
each pair of pseudovirus and plasma. Given a table of neutralization ID50s
measured for a panel of plasma samples against a panel of viruses, we
express the log titers as the sum of two terms and a constant:
log ID50(xy)  susceptibility(virus x)  potency(plasma y)  constant
(1)
which holds for all pairs (virus x, plasma y) in the table.
Minimizing the mean-square error of the above approximation across
the table yields the following:
log ID50(xy)  log geometric mean(virus x)
 log geometric mean(plasma y)  log geometric mean(all xy) (2)
Exponentiation yields
ID50(xy)  geometric mean(virus x)
 geometric mean(plasma y) ⁄ geometric mean(all xy) (3)
In the above expressions, geometric mean (virus x) is the geometric
mean ID50 of any selected virus x with all plasma samples in the table. The
geometric mean is used as an unbiased estimator of central tendency
because neutralization assay results exhibit log-normal, rather than nor-
mal, distributions. Similarly, geometric mean (plasma y) is the geometric
mean ID50 of any selected plasma sample y with all viruses in the table. The
overall geometric mean xy serves as a normalization constant. We vali-
dated correlation findings statistically using a permutation test, to ensure
that the correlation coefficient between observed ID50s and ID50s pre-
dicted by the row/column approximation was greater than by chance
alone. For any particular neutralization data set, we randomized (by per-
mutation without replacement) the log-transformed ID50 data 10,000
times, recomputed expected values from row/column averages of the ran-
domized data, and computed correlation coefficients between permuted
data and the approximated values at each iteration (see Table S5 in the
supplemental material). This gave a null distribution of correlation coef-
ficients, which we compared with the original r2 to obtain a resampled P
value.
Nucleotide sequence accession numbers. Sequences analyzed in this
study have the GenBank accession numbers listed below.
Pseudovirus Envs, U15121, AF259954, AF407152, AF407156, AF407158,
AF407160, AY423984, AY424079, AY424138, AY835434, AY835437 to
AY835441, AY835443 to AY835452, DQ187010, DQ388514 to DQ388517,
DQ411850 to DQ411854, DQ435682, DQ435683, EF042692, EF117255,
EF117258 to EF117266, EF117268 to EF117274, EF210726 to EF210730,
EF210732,EF210733,EF210735,EU166866,EU289183toEU289194,EU289198
to EU289202, EU513182 to EU513185, EU513187 to EU513190, EU513193 to
EU513196, EU513198, EU575148, EU575170, EU575786, EU575870,
EU576296, EU576299, EU577190, EU577213, EU885760 to EU885766,
FJ443575, FJ443670, FJ443744, FJ443808, FJ443999, FJ444017, FJ444047,
FJ444059, FJ444103, FJ444215, FJ444325, FJ444395, FJ444421, FJ444437,
FJ444529, FJ444561, FJ444600, FJ444612, FJ496194, FJ496204, FJ817366,
FJ817369, FJ817370, HM215260, HM215264 to HM215266, HM215269,
HM215270, HM215272 to HM215276, HM215278 to HM215281, HM215283,
PlasmaEnvs,HQ595767toHQ595806,HQ615962toHQ615988,HQ625565to
HQ625585, HQ625587 to HQ625590, HQ625592 to HQ625595, HQ625598,
HQ625600, HQ625602 to HQ625605, HQ690973, JF297221 to JF297233,
JF346900 to JF346919, JF680905, JF680937, KC748972 to KC749062.
RESULTS
Genetic variation in plasma and pseudovirus Envs. Full-length
gp160 sequences were obtained for the 219 Env-pseudotyped vi-
ruses and for a single SGA-derived Env from each of 170 plasma
Hraber et al.
12626 jvi.asm.org Journal of Virology
samples used for neutralization assays. Table 1 lists the clade dis-
tribution of all Envs and the infection stage of the pseudovirus
Envs. Figure 1 shows the phylogenetic diversity of plasma and
pseudovirus Envs. We could not extract an Env sequence from 34
plasma samples, so in those cases the clade of the infecting strain
was unknown. As expected, the nonrecombinant subtype se-
quences clustered with nonrecombinant Envs of the subtype ref-
erence alignment (Fig. 1). With gap-rich hypervariable loops ex-
cised, none of the 389 Env sequences studied shared over 93%
amino acid identity, and the most divergent sequences shared only
70% amino acid identity.
In addition to common CRFs 01 (Asia), 02 (West Africa), and
07 (China), we identified two CRFs (06 and 14) and 23 URFs
among virus Envs (6 AC, 5 AD, 4 BC, 6 CD, 1 ACD, and 1 BG) and,
among plasma Envs, one CRF10 and 11 URFs (4 AC, 3AD, 2
ABCD, 1 BD, and 1 CD) (76). Because URFs cluster with estab-
lished nonrecombinant clades of the phylogeny when comprised
primarily of one clade, we confirmed the URFs using the Recom-
binant Identification Program (RIP) (77) and in each case identi-
fied Env regions with over 90% similarity to more than one dis-
tinct M-group subtype (not shown). CRF07, a recombinant
lineage of clades B and C, carries a predominantly C-clade Env
(78) and forms a branch within clade C in Env phylogenies (Fig.
1). Similarly, CRF02 is a recombinant of A and G clades, mostly
clade A in Env, and associated with the A clade in Env phylogenies.
CRF02 is a much older lineage than CRF07 and branches outside



































































FIG 1 Phylogenetic diversity of Env sequences in the pseudoviruses and plasma samples used for neutralization assays. Env-pseudotyped virus (n  219) and
plasma-derived (n  171) sequence phylogeny followed the HIV-1 M group subtype reference Env distribution (n  39), with addition of CRFs 01, 02, and 07
reference strains. CRFs 01, 02, and 07 are important epidemic lineages in Thailand and other parts of Asia, West Africa, and China, respectively (36). Unique
recombinant forms, not known to be circulating because the particular combination of breakpoints that they exhibit has been identified only in the given
sequence, are indicated as “Other” (gray). Bootstrap support is indicated for nodes present in 60% or more of 500 resampled replicates. Note that the evolutionary
distances indicated by the branch lengths within the more recent CRF01 and CRF07 clades are substantially shorter than within the older epidemic clades (A, B,
C, D, G, and CRF02) (79).
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CRF02 and the A clade (Fig. 1) (79). CRF01 has traditionally been
designated clade E in Env (76, 79, 80), though no parental, full-
genome E-clade virus was ever isolated, making its genetic origins
particularly difficult to resolve (79, 81).
Adjustments for prescreened plasma effects. Prior to inclu-
sion in this study, a subset of plasma samples was selected from
larger plasma collections after screening for neutralization activ-
ity. Plasma samples from some clades were screened, while others
were not. For example, most (68 of 75, or 90%) of the clade C and
CRF07 plasma samples were chosen after they had been screened
for potency, versus few (6 of 74, or 8%) from clade B and none
from CRF01 (Table 1). Screening of plasma was conducted based
on the reasoning that plasma samples with little or no neutraliza-
tion activity would be of little value to identify neutralization se-
rotypes, a major initial goal of this study. Screening was performed
only when an excessive number of samples for a desired clade or
geographic region was available for downselection. Screening was
not performed when sample availability was limited; in these
cases, all available samples were included. Samples from all study
sites were brought together in this collection to enable a global
study. To analyze a data set with reduced impact of screening
selection bias, we applied a retroactive postscreening strategy
across all plasma samples. The postscreening strategy used a cutoff
that approximated the screening criteria to exclude plasma sam-
ples with the lowest activity, apply similar criteria across all collec-
tion sites and clades, and provide more-uniform sampling for
comparative analysis.
To assess the postscreening strategy, we tested whether neu-
tralization potency was greater against clade-matched viruses for
screened plasma samples than for nonscreened plasma samples
and found a significant difference (two-sided Wilcoxon test, P 
0.013; see Fig. S1A in the supplemental material). Similarly, com-
paring plasma neutralization potency against clade-mismatched
viruses indicated greater potency among screened than non-
screened plasma (see Fig. S1A; P  0.0077). Excluding the low-
titer plasma samples reduced these differences to lose statistical
significance (see Fig. S1B; P  0.73 for clade-matched viruses; P 
0.31 for clade-mismatched viruses). Thus, excluding weakly neu-
tralizing plasma samples helped to mitigate screening bias when
testing for clade effects.
Cross-reactive neutralization within and between clades. A
heatmap representation of ID50 neutralization results for all
44,758 plasma/pseudovirus combinations tested is shown in Fig.
2, sorted first by Env clade and then by plasma potency and pseu-
dovirus sensitivity within clades. This figure provides a compre-
hensive view of the neutralization data and illustrates the relation-
ships between screened samples and clades, as well as the time of
sampling of Env for pseudoviruses, some of which were collected
early in infection and some during chronic infection. An alterna-
tive view of the complete data, organized by hierarchical clustering
of shared reactivity and sensitivity patterns, is presented in Fig. S2
in the supplemental material. In general, plasma potencies were
significantly greater against clade-matched than mismatched vi-
ruses (paired Wilcoxon test, P  2.2  10	16). This was tested by
calculating two geometric mean ID50s for each plasma sample, one
for the comparisons to all clade-matched Envs and one for the
comparisons to all clade-mismatched Envs. The same outcome
was obtained with low-titer postscreened plasma samples ex-
cluded (Wilcoxon test, P  2.2  10	16). We also tested whether
screened plasma samples alone were more potent against clade-
matched than mismatched viruses and again found a significant
difference (paired Wilcoxon test, P  0.00085).
For a more detailed analysis of cross-reactive neutralization
effects, we identified the clades with the largest sample sizes for
both plasma and virus Envs and used these (A, B, C, CRF07, and
CRF01) for statistical comparisons. Consistently for each clade,
plasma neutralization potencies were significantly greater against
clade-matched than mismatched viruses (Fig. 3A). Paired, two-
sided comparisons indicated significant differences in geometric
mean ID50s for 4 of the 5 clades, i.e., B, C, CRF01, and CRF07, even
with Bonferroni’s correction applied to accommodate five tests
(all had P values of 0.01; specific Wilcoxon P values appear in
Fig. 3A). Clade A had fewer samples and shared the trend for
greater potency within than between clades (Fig. 3A).
The average sequence similarity between pseudovirus Envs and
plasma Envs, essentially by definition, was greater within than
between clades and particularly high for within-clade compari-
sons of CRF07 and CRF01 (Fig. 1 and 3B). CRF07 originated in the
1990s in China (79). It is essentially clade C in Env (Fig. 1), and it
is the least diversified lineage that we sampled. The CRF01 lineage
in Asia originated in Thailand in the late 1980s (80) and was more
diverse than CRF07. The A, B, and C clades are geographically
widespread and much older and more diversified clades (79, 111).
Rank ordering of clades by within-clade plasma potency corre-
sponded to the ranking by mean per-plasma Env similarity with
clade-matched Env pseudotyped viruses, except for clade A, which
had fewer samples than the others (Fig. 4). Essentially, less diverse
clades had greater within-clade potency, and the level of diversity
within clade reflected the age of the lineage. We discuss the impli-
cations of this more fully in Discussion below and provide more
detail regarding what is known about the timing of the origins of
these clades. We think these observations are relevant to potential
vaccine trial populations, as our CRF07 and CRF01 samples were
representative of the known diversity of these important lineages
in the Asian HIV epidemic. Both CRF07 and CRF01 were col-
lected from multiple geographically distant locations in China,
(Beijing, Yunnan, and Henan), and CRF01 samples were also ob-
tained in Thailand. To further verify that we did not have a biased
sampling of CRF01 and CRF07 strains, we compared them using
maximum likelihood trees to all CRF01 and CRF07 sequences
available in the database at Los Alamos (representing viruses ob-
tained from 322 CRF07 and 421 CRF01 distinctly infected indi-
viduals). The sequences of the CRF01 and CRF07 pseudovirus and
plasma Envs studied here were widely dispersed throughout their
respective genetic clades, with no evidence of clustering in our
sample (data not shown).
A simple, overall test for associations between virus infection
stage (i.e., early, intermediate, and late HIV-1 infection; the crite-
ria used for these categories are defined in Materials and Methods)
and nAb sensitivity was vulnerable to bias from differences in
sample size and cross-reactivity (Table 1). Rather than risk con-
founding cross-reactivity effects with infection stage, we com-
pared plasma potency against viruses stratified by infection stage
(early versus late) and with several alternative representations of
the data: (i) with and without low-titer plasma samples, i.e., using
the full data set or the postscreened subset; (ii) with and without
censored ID50s; and (iii) with intermediate-stage viruses excluded
or grouped with either early or late stages, for a total of eight
different representations. Because we did 16 Wilcoxon tests, we
Hraber et al.
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required an uncorrected P value of 0.003 for statistical signifi-
cance to allow for Bonferroni’s correction.
Surprisingly, there was a clear distinction in the sensitivity of
early and late viruses when virus and plasma Env clades did not
match, but no distinction was seen when they did match (a repre-
sentative example appears in Fig. 5). When plasma potencies
against clade-mismatched viruses from early and late infections
were compared, late viruses were more sensitive than early viruses
(P  6.4  10	10 by paired, two-sided Wilcoxon test). This effect
was consistently highly significant regardless of which data repre-
sentation was involved (every paired, two-sided Wilcoxon test
yielded P values of 7.1  10	7, among the 16 comparisons de-
scribed in the paragraph above, though only a representative ex-
ample is shown in Fig. 5). Moreover, it remained significant even
when we excluded the 11 most potently neutralizing clade C
plasma samples (P  5.2  10	8), the highest paired values shown
in Fig. 5, which could be considered outliers. In contrast, we were
unable to detect a difference in sensitivity between early and late
viruses assayed against clade-matched plasma samples. This effect
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FIG 2 Plasma neutralization potency and virus sensitivity from 205 chronically infected plasma samples against 219 Tier 2 pseudoviruses. Assay results are
presented as a heatmap of 44,758 ID50s. Rows and columns were sorted by geometric mean ID50 per clade, with more-sensitive viruses toward the top and
more-potent plasma samples toward the left. The color key histogram summarizes the percentage of observations in each given interval of ID50 values.
Annotation bands indicate Env pseudovirus clades (middle-left column), the infection stage from which virus was sampled or NA if unknown (left column),
plasma clades or NA if unknown (row above heatmap), and plasma samples screened against smaller panels of 6 to 18 viruses to ensure that neutralization
responses were detected to select from a larger plasma sample repository (gray bars, top row). Missing ID50 data are indicated by gray cells in the heatmap.
Variability of HIV-1 Neutralization
November 2014 Volume 88 Number 21 jvi.asm.org 12629
below, though a tendency for late viruses to be more sensitive to
neutralization was again evident. Notably, no comparison pro-
vided statistically significant support that early viruses were more
sensitive to neutralization than late viruses.
Influence of hypervariable regions on virus susceptibility
and plasma potency. We examined how neutralization titers vary
with length, net charge, and the number of putative N-linked glyco-
sylation sites in plasma and virus Env V1, V2, V4, and V5 hypervari-
able regions. The hypervariable regions are embedded within the
variable loops of gp120. The hypervariable regions mutate very rap-
idly, evolve in a manner dominated by insertions and deletions, and
carry different numbers and locations of potential N-linked glycosy-
lation sites and charged residues. The boundaries between hypervari-
able regions and regions that are more readily aligned in Env are
indicated in the Los Alamos HIV database available at http://hiv.lanl
.gov/content/sequence/HIV/MAP/annotation.html. We also com-
bined V1 and V2 (V1V2) hypervariable regions for analyses, because
they are spatially juxtaposed and surround regions known to contain
critical epitopes for PG9-like bnAbs (82, 83).
Virus V1V2 lengths were negatively correlated with geometric
mean neutralization ID50 per virus (Fig. 6A; Table 2) such that
viruses with longer V1V2 hypervariable regions were generally less
sensitive to neutralization than viruses with shorter loops. This
outcome remained significant whether or not the low-titer plasma
samples were excluded and whether or not the subset of only re-
active results was used (Fig. 6C). Lower levels of sensitivity were
also associated with lower net negative V1V2 charge and greater
numbers of potential N-linked glycosylation sites in the hyper-
variable regions of V1V2 (Table 2). Statistically significant associ-
ations were also found when V1 and V2 were considered indepen-
dently, though these were not as profound as when combined. We
were unable to detect associations between viral sensitivity deter-
mined by ID50s and V4 or V5 hypervariable region characteristics
across the full data set (Table 2).
Significant associations were found also for geometric mean
ID80 per virus with V1 and V2 properties, both separately and
combined (see Table S1 in the supplemental material). Some sup-































































FIG 3 Greater plasma potency within than between clades. (A) Plasma potency, computed as geometric mean ID50, was significantly greater against clade-
matched viruses (filled symbols, left group per plasma clade) than against clade-mismatched viruses (open symbols, right group per clade). Test results from
URFs were omitted, as were weakly neutralizing, screened plasma samples (see the text). Lines connect paired means from the same plasma sample. Paired,
two-sided Wilcoxon tests gave P values of 0.00012 for CRF07 (n  14) and also for CRF01 (n  14), 0.078 for A (n  7), 3.3  10	7 for B (n  35), and 8.9 
10	7 for C (n  48). CRF02 is also shown (n  1). Clade C viruses were excluded from analysis of CRF07 plasma potency, and vice versa, as CRF07 is an outgrowth
of C. (B) Average similarity between plasma and virus Envs was greater within (filled symbols, left group per clade) than between (open symbols, right) clades.
Thick lines show the median, and thin lines show interquartile ranges (25th and 75th percentiles) per distribution.
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length and number of glycosylation sites was found when nonre-
active plasma samples were excluded, though this outcome was
not supported by ID50s with virus sensitivity computed in aggre-
gate across plasma samples (see Table S1 in the supplemental ma-
terial).
Interestingly, the direction of neutralization-response associa-
tions was reversed when Env sequences in the plasma samples
were considered. Positive associations were found between the
geometric mean neutralization ID50 per plasma and the V1V2
length of plasma Envs (Fig. 6B and D), regardless of whether or
not the low-titer plasma samples and nonreactive assay results
were included (Table 3). That is, plasma samples from individuals
with Envs that had longer V1V2 loops tended to be more potent
than plasma samples from which the Envs contained shorter
V1V2 loops. Because long V1V2 loops were associated with resis-
tance in the pseudotyped Envs (Fig. 6A and C), this raises the
hypothesis that viruses from individuals with more-potent nAbs
carried Envs with greater overall resistance as a consequence of
immune escape from effective antibodies and that this resistance
was at least in part manifested by longer V1V2 loops. This agrees
with our finding that Envs with longer loops tend to be more
resistant to plasma neutralization. We found no robust, statisti-
cally significant support for associations between average neutral-
ization response and plasma Env V4 or V5 properties across all
data (Table 3; see also Table S1 in the supplemental material).
Anomalous profile among Thai plasma samples. Plasma
samples from Thailand, primarily from CRF01 infections but also
from two B-clade infections, shared a distinctive neutralization
profile relative to the other plasma samples. Principal components
analysis (PCA) clustered a B-clade plasma with 11 CRF01 plasma
samples, all from Thailand (Fig. 7). Similarly, hierarchical cluster-
ing of the ID50 values formed two distinct groupings of plasma
samples from Thailand, one group comprised of a B-clade plasma
together with 10 CRF01 plasma samples and another bootstrap-
supported group of a B-clade plasma with two from CRF01 (see
Fig. S2 in the supplemental material). Hierarchical clustering of
neutralization values joined 14 of 15 plasma samples from Thai-
land together into one cluster with less-robust bootstrap support
(not shown, but see Fig. 1 in reference 58). While other serological
clustering patterns are evident in the heatmaps shown in Fig. 2 and
in Fig. S2 in the supplemental material, the Thai B and CRF01
plasma samples had a particularly distinctive pattern. Of note,
none of the plasma samples from Thailand had been screened for
enhanced neutralization activity.
While diverse Env-pseudotyped viruses were susceptible to
neutralization by these plasma samples, k-means clustering (k 
2) of 219 virus ID50s for the 10 CRF01 and 1 B-clade plasma from
Thailand yielded virus groups with high (n  86) or low (n  107)
susceptibility supported by over 70% of bootstrap replicates (26
viruses were not stably assigned to either group). CRF01 viruses
were enriched in the susceptible group (15 CRF01s versus 71 non-
CRF01s) relative to the group resistant (3 CRF01s versus 104 non-
CRF01s) to these plasma samples from Thailand (Fisher’s exact
test, P  0.00007, odds ratio [OR]  0.14, 95% confidence inter-
val [CI]  0.025 to 0.51). Given this, we hypothesized that the
CRF01 viruses may be exposing a distinctive CRF01 clade-specific
epitope resulting in this shared serological response and that the
two Thai donors with this serotype that had a B-clade Env-infect-
ing sequence might have been dually infected with undetected
CRF01 that could be contributing to this serotype.
To seek evidence of mixed CRF01/B clade coinfections in these
two cases, approximately 30 (range, 29 to 32) additional sequences
were obtained from each plasma sample. Only B clade sequences
were found. If dual-clade infections were present, they were rare in
both plasma samples. Additional analysis with the recombination
identification program (RIP) did not show significant support for
between-clade recombination among any of the B-clade se-







































07 01 C A B
Clade
B
FIG 4 Within-clade plasma potency distributions followed rank order of similarity distributions between plasma and virus Envs. Within-clade data from Fig. 3
are ordered by decreasing values. (A) Plasma potency, computed as geometric mean ID50, was greatest against clade-matched pseudoviruses for CRF07, followed
by CRF01 and then clades C, A, and B. (B) Mean similarity between plasma and clade-matched pseudovirus Envs roughly followed the rank ordering of plasma
potencies per clade, with greater similarities within more recently emergent CRF07 and CRF01 than nonrecombinant clades. Thick lines show the median, and
thin lines show interquartile ranges (25th and 75th percentiles) per distribution.
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sequences (see Fig. S3 in the supplemental material) showed no
evidence for cross-clade coinfection among sequences from the
CRF01 infection or either of the B-clade infections. Aside from the
possibility of transient or rare CRF01 superinfecting subpopula-
tions in both B-clade plasma samples, which we could not elimi-
nate, this suggests that the shared serological pattern may not be
clade related, as it is found in both CRF01 and B-clade infections
among plasma samples only from Thailand. Rather, this finding
might be explained by a host-driven serological response, possibly
due to host genetics causing shared patterns of cross-reactive re-
sponses to similar immunogens, or by preexisting immunity that
has a shared regional aspect (84).
Corroboration of major findings by mixed-effects logistic re-
gression. Analyzing average neutralization responses across
plasma samples or viruses with different characteristics identified
the correlations with neutralization sensitivity described above.
Here we used mixed-effects logistic regression to evaluate whether
the significant outcomes could be corroborated by an alternative
analysis method that can represent variation due to random ef-
fects; in these models, we treated the plasma and the virus as ran-
dom variables. Because 19,169 of 44,758 (42.8%) ID50 measure-
ments were below the level of detection, we used a logistic model
that modeled neutralization outcome as a binary variable, based
on whether or not the neutralization score was above the median
ID50 for the full data set. These analyses also allowed us to explore
the relative impacts of different variables on neutralization and to
test for possible interactions between them. A complete descrip-
tion appears in Text S2 in the supplemental material; the main
findings are summarized here.
We considered several models to accommodate nuances of the
experimental design. In the first model, we defined four match
levels based on degrees of Env similarity between viruses and
plasma, in accordance with what is shown in Fig. 4B. Level 1 re-
ferred to CRF07 plasma and CRF07 virus, which were the most
similar, level 2 to CRF01 plasma and CRF01 virus, level 3 to other
within-clade neutralization scores (including C plasma against
CRF07 virus and vice versa), and level 4 to between-clade neutral-
ization. We also included in the model the V1V2 lengths of plasma
and virus Envs, the stage of the infection from which the virus was
sampled (early or late), and whether or not the plasma sample was
screened (see Table S2 in the supplemental material). The most
highly significant effect was for matching CRF01 plasma with vi-
rus (P  1.2  10	7), followed by the impact of screening (P 
0.002). Matches between CRF07 plasma and virus were still sig-
nificant (P  0.013), and the most negative association was the
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FIG 5 Virus clade interacted with infection stage effects on plasma potency. Among clade-mismatched viruses, plasma potency (geometric mean ID50) was
significantly greater against viruses from late (Fiebig V through chronic) than early (Fiebig I-IV) infections (paired, two-sided Wilcoxon test, P  6.4  10	10,
left). However, among clade-matched viruses, no evidence was found for differences in neutralization between early and late infections (paired, two-sided
Wilcoxon test, P  0.33, right). Low-titer plasma and censored values were excluded. Colored lines connect pairs of plasma samples. Thick black lines indicate
median ID50s. Thin black lines indicate 25th and 75th percentiles.
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found no statistical support for an interaction between the stage of
the virus and the match level, despite the result shown in Fig. 5, in
which geometric mean ID50s per plasma differed significantly only
against clade-mismatched (level 4) viruses when computed sepa-
rately for early and late viruses. However, we did find that late
viruses were significantly more sensitive to neutralization than
isolates from early infections (P  0.015).
Consistent with the results shown in Fig. 6, longer total V1V2
loops were associated with more-resistant viruses (P  0.02), sug-
gesting that insertions in these regions facilitated acquisition of
resistance. Also, Envs with longer V1V2 loops were associated
with more potent plasma neutralization activity (P  0.03), sup-
porting the idea that potent plasma samples had selected for more
resistant contemporaneous viruses with longer V1V2 hypervari-
able regions. Of note, the estimated standard deviations of the
random effects for plasma and virus were 1.8 and 0.99, respec-
tively. Thus, the random effect for plasma is about twice that of
viruses. Further, the magnitude of the estimated fixed effects was
typically smaller (compared with the standard error) than the ran-
dom effects (see Table S2 in the supplemental material).
We confirmed that these outcomes did not result from the
screening effect by implementing a second model that used a sim-
plified representation of clade matching and virus infection stages,
together with exclusion of censored values and application of the
postscreening criterion described earlier. Again, effects of clade
matching, virus stage, plasma Env V1V2 length, and virus V1V2
length were supported by statistical significance (see Table S3 in
the supplemental material). The estimated standard deviations for
random effects of plasma and virus were 1.2 and 1.0, respectively,
suggesting that the greater contribution of plasma random effects
in the previous model was influenced by the low-titer ID50s, par-
ticularly for low-titer plasma samples that satisfied the postscreen-
ing criterion.
In a third model, we considered each of the clades indepen-
dently, instead of grouping them into sequence similarity-














































































































































































































































































































































































































































































































































































































































































































































FIG 6 Short V1V2 loops were associated with increased virus sensitivity and reduced plasma potency. (A and B) Negative association between virus V1V2 lengths
and geometric mean ID50 per virus (Kendall’s   	0.127, P  0.006, n  219) (A) contrasts with a positive association between plasma V1V2 lengths and
geometric mean ID50 per plasma (  0.128, P  0.0156, n  170) (B). (C and D) Similarly, with low-titer plasma and nonreactive (censored) ID50 assay results
excluded, the negative association for virus Envs (  	0.213, P  4.44  10	6, n  219) (C) and positive association for plasma Envs (  0.172, P  0.00462,
n  129) (D) remain. Symbols indicate the clade of each virus (left) or plasma sample (right), using the same colors for clades as in previous figures (“O” indicates
other CRF/URF). Dashed lines were fit by least-squares regression.
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of the clades had statistically significant positive interaction esti-
mates for within-clade responses (Table 4). The relative impact of
the within-clade advantage ranked highest for CRF07 and CRF01
and lowest for clade C (Table 4). Close examination of Fig. 3A
suggests that the minimal impact of the within-clade advantage
for clade C may be explained by the observation that a small subset
of plasma samples from individuals with C-clade infections re-
tained potent cross-clade reactivity. Most of the between-clade
TABLE 2 Correlation of virus Env hypervariable loop properties (length, net charge, and number of potential N-linked glycosylation sites) with
geometric mean plasma ID50 per virus (n  219 viruses)
Property
All dataa Positive valuesb No-low-titer plasma samplesc
Positive and no-low-titer
plasma samplesd
e pf qg  p q  p q  p q
V1 lengthh 	0.08 0.101 0.213 	0.14 0.003 0.026** 	0.09 0.049 0.129 	0.13 0.004 0.031**
V1 netchgi 0.19 2e-04 0.003*** 0.13 0.011 0.048** 0.20 1e-04 0.002*** 0.13 0.007 0.036**
V1 glycosj 	0.01 0.800 0.739 	0.06 0.274 0.404 	0.02 0.704 0.699 	0.05 0.351 0.468
V2 length 	0.06 0.182 0.311 	0.13 0.006 0.034** 	0.06 0.174 0.305 	0.13 0.007 0.036**
V2 netchg 0.03 0.555 0.619 0.10 0.042 0.119 0.04 0.434 0.545 0.10 0.049 0.129
V2 glycos 	0.05 0.344 0.464 	0.15 0.004 0.031** 	0.05 0.314 0.440 	0.14 0.007 0.036**
V1V2 length 	0.13 0.006 0.034** 	0.22 3e-06 8e-05*** 	0.14 0.002 0.025** 	0.21 4e-06 1e-04***
V1V2 netchg 0.13 0.006 0.034** 0.13 0.006 0.034** 0.14 0.004 0.031** 0.14 0.004 0.031**
V1V2 glycos 	0.05 0.308 0.438 	0.15 0.003 0.029** 	0.06 0.229 0.363 	0.14 0.007 0.036**
V4 length 0.00 0.999 0.782 	0.07 0.160 0.291 	0.01 0.909 0.763 	0.05 0.261 0.394
V4 netchg 0.00 0.962 0.770 0.04 0.461 0.555 0.01 0.840 0.743 0.04 0.452 0.552
V4 glycos 0.01 0.785 0.736 	0.05 0.322 0.444 0.01 0.820 0.741 	0.04 0.412 0.528
V5 length 	0.04 0.463 0.555 	0.10 0.047 0.129 	0.04 0.393 0.508 	0.09 0.070 0.166
V5 netchg 	0.04 0.458 0.555 	0.03 0.537 0.606 	0.04 0.426 0.539 	0.04 0.482 0.566
a Censored values taken as given, i.e., placeholder constants of 10 for ID50s below 20.
b Censored values treated as missing, i.e., only positive assay results were used.
c Plasmas with geometric mean ID50 below 20 were excluded from these comparisons.
d Plasmas with low geometric mean ID50s and censored values were excluded from these tests.
e Kendall’s  as computed by the eponymous R package.
f Two-sided P value on the null hypothesis of no correlation.
g False-discovery rates computed from 360 P values by the q-value package. Significance levels: *,* q  0.05; ***, q  0.01.
h Hypervariable loop boundaries are defined in Text S2 in the supplemental material and are not simply cysteine-cysteine.
i netchg, net charge, i.e., number of K, H, and R sites minus the number of D and E sites.
j glycos, number of potential N-linked glycosylation sites following the Nx[ST] motif, with x not P.
TABLE 3 Correlation of plasma Env hypervariable loop properties (length, net charge, and number of potential N-linked glycosylation sites) with
geometric mean ID50 per plasma sample
Property
All dataa Positive valuesb No-low-titer plasma samplesc
Positive and no-low-titer
plasma samplesd
e pf qg  p q  p q  p q
V1 lengthh 0.08 0.144 0.273 0.06 0.258 0.394 0.15 0.017 0.062* 0.13 0.027 0.088*
V1 netchgi 	0.02 0.696 0.696 0.01 0.804 0.739 0.00 0.961 0.770 0.01 0.827 0.742
V1 glycosj 0.09 0.118 0.240 0.11 0.064 0.155 0.18 0.006 0.034** 0.18 0.005 0.031**
V2 length 0.10 0.068 0.163 0.10 0.068 0.163 0.04 0.561 0.623 0.03 0.609 0.646
V2 netchg 0.15 0.011 0.048** 0.12 0.038 0.111 0.16 0.012 0.051* 0.13 0.053 0.136
V2 glycos 0.01 0.931 0.763 	0.01 0.898 0.763 	0.03 0.691 0.694 	0.04 0.569 0.627
V1V2 length 0.13 0.016 0.061* 0.13 0.017 0.062* 0.17 0.004 0.031** 0.17 0.005 0.031**
V1V2 netchg 0.06 0.259 0.394 0.07 0.180 0.310 0.10 0.107 0.223 0.10 0.135 0.261
V1V2 glycos 0.09 0.110 0.225 0.09 0.108 0.223 0.16 0.016 0.061* 0.14 0.030 0.093*
V4 length 	0.03 0.591 0.633 	0.07 0.205 0.336 	0.04 0.486 0.568 	0.07 0.228 0.363
V4 netchg 	0.01 0.835 0.742 0.02 0.747 0.729 0.00 0.987 0.775 0.03 0.658 0.682
V4 glycos 	0.07 0.265 0.395 	0.08 0.165 0.294 	0.01 0.925 0.763 	0.01 0.852 0.746
V5 length 0.01 0.876 0.758 	0.01 0.906 0.763 0.08 0.227 0.363 0.05 0.475 0.566
V5 netchg 	0.01 0.814 0.739 	0.01 0.927 0.763 0.03 0.650 0.679 0.01 0.920 0.763
a Censored values taken as given, i.e., placeholder constants of 10 for ID50s below 20 (n  170).
b Censored values treated as missing, i.e., only positive assay results were used (n  170).
c Plasma samples with geometric mean ID50 below 20 were excluded from these comparisons (n  129).
d Both plasma samples with low geometric mean ID50s and censored values were excluded (n  129).
e Kendall’s  as computed by the eponymous R package.
f Two-sided P value for the null hypothesis of no correlation.
g False-discovery rates computed from 360 P values by the q-value package. Significance levels: *, q  0.10; **, q  0.05.
h Hypervariable loop boundaries are defined in Text S2 in the supplemental material and are not simply cysteine-cysteine.
i Net charge, i.e., number of K, H, and R sites minus the number of D and E sites.
j Number of potential N-linked glycosylation sites following the Nx[ST] motif, with x not P.
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mismatched plasma and virus combinations had negative interac-
tions, with a few interesting exceptions. Clade C and CRF07
plasma samples and viruses, not surprisingly, had a positive inter-
action, consistent with CRF07 essentially being clade C in Env, a
recent outgrowth of the clade C lineage (Fig. 1). More unexpect-
edly, CRF02 viruses had a positive interaction with CRF01 plasma
samples, and the capacity to neutralize CRF02 viruses relatively
potently may be an aspect of the distinctive serological profile
associated with Thai viruses. Plasma samples from clade B had a








































































































































































































FIG 7 Clustering plasma samples by neutralization outcomes with principal components analysis (PCA) shows Thai plasma grouping. The boxed region
identifies 12 Thai plasma samples with distinct, shared profiles, including T500108_503963 from a B-clade infection clustered with CRF01 plasma samples
(T500204_502281, T500207_503006, T500104_276248, T500105_293735, T500206_614109, T500208_504258, T500105_500617, T500207_509989,
T500108_503963, T500107_535902, T500207_502102, and T500106_501602). Binary-transformed ID50s (1 for above and 0 for below the TZM-bl assay limit of
detection) per plasma are projected onto orthogonal axes that together capture 22.49% of the total variance. This rendering gives a simplified summary of plasma
neutralization profiles on uncorrelated axes, which include as much of the overall variation as possible, so plasma samples with similar profiles appear close
together. Symbols indicate plasma clade (“O” for other CRFs and URFs, “U” for unknown due to inability to amplify from the plasma). PCA of neutralization
data with log rank transformations yielded similar prominent groupings of the Thai plasma samples (not shown).
TABLE 4 Estimated log-odds ratios for interactions between virus and plasma cladea
Virus clade
Plasma sample-infecting strain clade
CRF07 CRF01 CRF02 Clade A Clade B Clade C Clade D
CRF07 1.288a 	0.532 NSb NS 	0.494 0.700 0.389c
CRF01 	0.546 1.295 	0.739 NS NS NS 	0.137
CRF02 	0.473 0.877 1.184 NS 	0.304 	0.363 0.680
Clade A NS 	1.184 NS 0.895 0.316 NS 0.245
Clade B 	0.224 	0.750 NS NS 0.802 	0.230 	0.795
Clade C 0.742 	0.680 NS NS 	0.219 0.430 0.087
Clade D 	1.116 NS NS NS NS NS 	1.346
Clade G 	0.501 	0.460 	0.265 0.440 	0.085 	0.007 	0.878
a Bold values indicate where the clade of the infecting strain of the plasma samples matches that of the test viruses. Only statistically significant interactions are shown. Positive
values among within-clade interactions indicate that plasma samples and viruses from the same clade typically increase the proportion of ID50 values above the median value of 28;
the value indicates the magnitude of the effect. Most off-diagonal estimates are negative, which indicates that a mismatch between plasma sample and virus clades decreases the
proportion of ID50 values above the median ID50. Because the estimated effects for each factor total zero, some estimates are determined by the others; italicized values are implied
by the zero-total contrast and do not have an estimated standard deviation or P value.
b NS, not significant.
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slightly enhanced ability to recognize clade A viruses relative to
other clades (see Table S4 in the supplemental material).
Modeling neutralization outcomes as row/column effects. It
is well known that some viruses (e.g., tier 1 viruses) are highly
susceptible to neutralization by HIV-1-positive plasma samples,
while others (e.g., tier 2 viruses) are generally more resistant (4,
85). It is also well known that some plasma samples are generally
more potent across a range of HIV-1 viruses, while other plasma
samples are generally less potent (16, 17). What is not well known
is the degree to which the variation (technically, the variance) of
log-transformed titers in a table (i.e., a tabular data matrix, with
rows and columns representing viruses and plasma samples, re-
spectively) of checkerboard-style HIV-1 neutralization assay re-
sults can be represented simply as the sum of a susceptibility score
for each Env and a potency score for each plasma sample. The
susceptibility score of an Env is the log-transformed geometric
mean titer (GMT) across plasma samples for that Env. Similarly,
the plasma potency score is the log-transformed GMT across Envs
for that plasma. Residual ID50s, obtained by subtracting approxi-
mated from observed ID50s, represent neutralization signal spe-
cific to each interaction not captured fully by the approximation
based on the expected behavior of the plasma and the virus (see
Fig. S4 in the supplemental material).
A simple approximation for log-transformed titers based on
the sum of the Env susceptibility and plasma potency scores
(equation 2) accounted for roughly one-half of the variance in the
neutralization data presented herein, as the r2 (Pearson correla-
tion coefficient, squared) between approximated and measured
log-ID50 values was 0.49. This was significantly greater than would
be expected if the same values were redistributed randomly over
the neutralization data table (P  0.0001 by permutation testing,
based on 10,000 randomizations of the data; see Materials and
Methods). The randomized data, as expected, gave very low r2
values, between 0.006 and 0.014 (see Table S5 in the supplemental
material). In other words, roughly one-half of the variance in the
table of log-transformed titers was accounted for by simply adding
the overall scores from Env susceptibility and plasma potency
(Fig. 8).
We confirmed this unexpected observation with other, previ-
ously published checkerboard-style HIV-1 neutralization data
sets. In each case, the “row/column approximation” accounted for
roughly one-half to two-thirds of the variance, depending on the

























FIG 8 Approximated neutralization ID50s were correlated with observed ID50 values and explained one-half of the observed variation. ID50s were approximated
as geometric mean ID50 per plasma sample times geometric mean ID50 per virus, divided by overall geometric mean ID50. The solid line indicates least-squares
fit (P  2.2  10	12, Pearson’s r  0.702). The r2 corresponds to 49.3% of all variance. To reduce overplotting, jitter was applied when rendering the censored
ID50s (20, 42.8% of all ID50s).
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neutralization table and the extent of phylogenetic diversity rep-
resented among assays performed. Analysis of neutralization data
based on plasma samples from clade C infections in India com-
pared to Env-pseudotyped viruses of diverse clades, including the
C isolates from India used in the study by Kulkarni et al. (54),
produced an r2 of 0.57. For the diverse multiclade neutralization
table used by Seaman et al. (4), r2 was 0.46. For B-clade plasma
samples tested against a multiclade panel in the neutralization
table used by Doria-Rose et al. (86), r2 was 0.66, i.e., two-thirds of
the variance of log-transformed titers is accounted for by simply
adding susceptibility and potency scores. All of these r2 scores
were significantly greater than expected from random data by per-
mutation testing (P  0.0001; see Table S5 in the supplemental
material).
Thus, the results for the row/column effect based on the cur-
rent neutralization data were confirmed with independent neu-
tralization data and demonstrate that specific interactions be-
tween Envs and constituent antibodies of plasma are not the
exclusive dominating factor determining neutralization titers. In-
dividual properties of an Env, as summarized by its susceptibility
score, and of antibodies in plasma, as summarized by the potency
score, are at least equally, if not more important.
DISCUSSION
This large study permitted an unambiguous resolution of whether
there is a within-clade enhancement of neutralization sensitivity
and enabled us to detect a dependency of the magnitude of this
effect on the age of the HIV-1 regional epidemic. Neutralization
potency was generally greater when plasma from a person infected
with a given clade was tested against Envs from that same clade,
and the within-clade advantage was more pronounced for the
more recent, less diverse CRF07 and CRF01 Asian clades than for
the older A, B, and C clades (Fig. 1). Thus, the potential benefit of
a within-clade regional vaccine is diminishing substantially on the
time scale of decades. CRF07 is thought to have originated in
Yunnan in 1993 (79, 87, 88) and subsequently spread throughout
China to become an epidemiologically significant lineage. The
Thai CRF01 epidemic dates to the late 1980s, going from no de-
tected cases in 1986 to over 5,000 cases by 1988 (89, 90). The A, B,
and C clades originated much earlier (91), with estimates for the
most recent ancestor of the B and C clades in the 1960s and the A
clade even earlier (89, 92). The potential impact of the within-
clade advantage seen here may be relevant for antibodies in gen-
eral, not only nAbs. A possible consequence of the diminishing
impact with age of the epidemic is that the modest protective effect
observed in the RV144 Thai vaccine trial (15), which correlated
with antibodies to the V2 and V3 regions of gp120 (14, 93–95),
may be difficult to emulate in other populations, where the virus is
more diverse, even if the HIV-1 epidemic in the targeted popula-
tion is dominated by a single clade. Despite the within-clade ad-
vantage, most plasma samples had extensive cross-clade neutral-
izing activity.
A cluster of 12 plasma samples from Thailand had a particu-
larly distinctive serologic pattern, shared by plasma from 11
CRF01 infections and a single B-clade infection (Fig. 7; see also
Fig. S3 in the supplemental material). Another small Thai sero-
logic cluster (see Fig. S3) included both one B-clade and two
CRF01 plasma samples. Plasma samples from B-clade infections
outside Thailand did not share these patterns. One hypothesis to
explain the clustering of B and CRF01 plasma samples from Thai-
land is that subjects with B-clade Env sequences may have been
coinfected with CRF01 (96). We sequenced 30 viruses from each
of the Thai individuals having B-clade infections and found no
traces of CRF01 coinfection; however, CRF01 may have been pres-
ent at levels too low to detect by this method. Also, transiently
detected superinfections have been reported (97, 98). Alterna-
tively, host factors, whether genetic or environmental (e.g., expo-
sure to an HIV-1 cross-reactive epitope from an organism in the
Thai communities where the samples were obtained), might ex-
plain the shared serological profiles (84).
Our study also permitted an examination of whether transmis-
sion selects viruses that are generally more sensitive to heterolo-
gous neutralization than viruses isolated in chronic infection. Pre-
sumably, transmitted/founder (T/F) viruses undergo selection for
transmission and replication fitness prior to the onset of adaptive
immunity. A manifestation of this may be the shorter hypervari-
able loop lengths that tend to be selected at transmission (99–101),
which in turn may better expose key neutralization epitopes. Also,
selection of mutations associated with increased Env expression
levels might enhance both infectivity and neutralization sensitiv-
ity (102–104). Chronic viruses, on the other hand, might acquire
general features associated with neutralization resistance under
continuous selection by autologous immune responses. Previous
studies have yielded conflicting results as to whether T/F viruses
are slightly more sensitive to neutralization than chronic viruses
(99, 105, 106). Our results do not support the notion that T/F
viruses are more sensitive to neutralization. Indeed, we found
early viruses to be less sensitive than late viruses when assayed with
clade-mismatched plasma samples; however, no difference was
found when the viruses were assayed with clade-matched plasma
samples. We do not have a clear biological explanation for these
statistically supported observations, which were contrary to our
expectations. The collective genetic features required for trans-
mission fitness and initial replication in a new host may have a
negative impact on neutralization in ways not yet understood,
despite the fact that early variants have features that one might
expect a priori to favor neutralization sensitivity.
We also explored the relationship between neutralization and
gp120 hypervariable regions. While the characteristics of these
regions have not been considered in the immunogen selection
process of earlier vaccine efficacy trials, they may be important for
both vaccine design and the interpretation of vaccine-elicited an-
tibody responses. The evolution of hypervariable regions is dom-
inated by insertion and deletion events (69), and they are under
intense selective pressure in HIV-infected individuals (35, 69,
107). Consequently, they are subject to extreme length variation
(e.g., the V1 hypervariable region varies between 5 and 42 amino
acids among the Envs in this study). Given this, they are not read-
ily aligned, and they violate model assumptions inherent in most
phylogenetic methods. The V1, V2, V4, and V5 loops contain
hypervariable regions. The V3 loop, while variable, does not con-
tain a hypervariable region.
Among hypervariable regions, the V1V2 loops, taken together,
were most influential for both neutralization susceptibility of Env-
pseudotyped viruses and overall neutralization activity in plasma
samples. Env-pseudotyped viruses with greater resistance to
plasma neutralization had V1V2 loops that were longer, with
more N-linked glycosylation sites and more negatively charged
residues, suggesting that these features facilitate immune evasion.
These same features, when present in plasma Envs, were associ-
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ated with broader, more potent plasma neutralization activity,
suggesting that V1V2-mediated escape from autologous nAbs
helped drive the response to greater neutralization breadth (108).
No associations were found with V4 characteristics, and only a
moderately significant association was seen between greater neu-
tralization sensitivity and viruses with shorter and less-glycosy-
lated V5 regions. As part of the contact region for CD4 binding site
neutralizing antibodies (30), the V5 hypervariable region is of par-
ticular interest. These observations suggest that V1V2 plays a
more dominant role than V4 and V5 in shaping overall neutral-
ization susceptibility of viruses and nAb responses in plasma. Spe-
cific bnAbs may, however, have distinctive patterns of variable
loop characteristic sensitivity that were not evident based on this
study of polyvalent plasma samples.
Interestingly, a general neutralization susceptibility score as-
signed to each Env based on its average sensitivity, combined with
the average potency of the plasma, approximated with surpris-
ingly good accuracy the individual neutralization titers in our
data. We had not anticipated such a finding, given that a priori the
most important factor that influences the level of neutralization
against specific sets of Envs would be differential exposure and
conservation of the particular epitopes recognized by the domi-
nant antibody responses in the plasma samples. Our findings may
be related to recent independent work linking the general neutral-
ization susceptibility of an Env to its physical properties (109).
The intrinsic Env reactivity (ER), defined as the degree of neutral-
ization and binding seen with soluble CD4, when combined with
an antibody perturbation factor (PF), which characterizes the
general neutralization potency of a nAb in terms of certain phys-
ical properties, was shown to approximate the actual neutraliza-
tion potency of a particular HIV-1-nAb combination (109, 110).
How our computationally defined susceptibility and potency
scores for Envs and plasma samples relate to the physically defined
ER and PF characteristics of Envs and nAbs, respectively, is under
investigation.
The results presented here may help to inform vaccine design
in several ways. In particular, the impact of V1V2 attributes
should be carefully considered. Future studies could explore
whether multivalent vaccine candidates that comprise a range of
V1V2 characteristics, including viruses with resistance-associated
loop characteristics, might be advantageous for driving neutral-
ization breadth. Alternatively, it may be best to optimize V1V2 for
sensitivity, as this might improve access to key epitopes. The prox-
imity of these hypervariable regions to PG9-like broadly neutral-
izing epitopes (82, 83) and to an epitope of a nonneutralizing
antibody response associated with a reduced risk of infection in
RV144 (14, 93–95) emphasizes their importance. The fact that
transmission events tend to select for short hypervariable regions
(99–101) provides an additional reason to emphasize short loops
in vaccine strains, so that they better match their primary target.
We note that the V1V2 features identified here did not impart a
highly neutralization-sensitive tier 1 phenotype on any of the vi-
ruses studied. Rather, these features influenced a spectrum of neu-
tralization sensitivities within the boundaries of the tier 2 pheno-
type that is common for most circulating strains. A short V5
domain with few glycosylation sites was also associated with Env
neutralization, but only when using ID80s as the measure of re-
sponses. Because CD4 and CD4 binding site bnAbs make direct
contact in the region around the hypervariable part of V5 (30), it
may also be prudent to choose vaccine immunogens with minimal
V5 hypervariable stretches.
These data also indicate that including Env immunogens that
match the genetic subtype of the major circulating variants in the
region where the vaccine will be given may afford additional ad-
vantages for optimal within-clade neutralization. However, the
high prevalence of cross-clade neutralization seen here suggests
that clade-mismatched Envs are also useful for generating neutral-
ization responses, though the average responses are reduced.
Thus, the idea of a more global vaccine need not be dismissed,
particularly if vaccine antigens are designed specifically to en-
hance cross-reactive neutralization responses through inclusion
of polyvalent mixtures or by focusing the immune response on the
most highly conserved epitopes.
The results presented here also have implications for assess-
ments and interpretations of vaccine-elicited nAb responses. Ap-
propriate clade representatives and realistic distributions of the
intrinsic reactivity of Env reagents both might be important for
selection of assay reference strains that best represent the target
population. In this regard, a new global panel of reference strains
was shown to be comparable to clade-specific panels for predict-
ing clade-specific nAb responses in HIV-1 infection (58). How-
ever, it is not yet known how well this panel will predict vaccine-
elicited clade responses. The small but statistically significant
advantage for clade-matched neutralization seen here suggests
that clade-matched reference strains may be an important adjunct
to the global panel for optimal detection of neutralization potency
and breadth. The age of the epidemic might be another important
consideration for reference strain selection, especially for the
more recent epidemics in Thailand and China, where inclusion of
contemporary regional viruses may best reflect the potential value
of vaccine-elicited nAbs. Finally, the interesting and potentially
host-driven serotype found among Thai samples suggests that
host factors and examination of preexisting immune cross-reac-
tive memory cells may be an important determinant, which might
sometimes impact patterns of immune response.
In concert with the finding that nearly all infected subjects have
the potential to develop antibodies that neutralize a substantial
proportion of heterologous viruses rather than an exclusive few
(17), the prospect for vaccine immunogens to stimulate bnAbs
against diverse HIV-1 Envs remains a promising and reasonable
objective.
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